Capital Fund Management (CFM)
CRSP icon

Capital Fund Management (CFM)’s CRISPR Therapeutics CRSP Stock Holding History

Capital Fund Management (CFM)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,600
Closed -$564K – 2488
2025
Q2 		$564K Buy
+11,600
New +$449K ﹤0.01% 2164
2025
Q1 		– Sell
-94,100
Closed -$3.7M – 2052
2024
Q4 		$3.7M Buy
94,100
+55,900
+146% +$2.64M 0.01% 1227
2024
Q3 		$1.79M Sell
38,200
-36,000
-49% -$1.83M ﹤0.01% 1486
2024
Q2 		$4.01M Sell
74,200
-44,000
-37% -$2.55M 0.01% 1057
2024
Q1 		$8.06M Buy
118,200
+100,900
+583% +$7.22M 0.02% 836
2023
Q4 		$1.08M Buy
17,300
+4,900
+40% +$271K ﹤0.01% 1809
2023
Q3 		$563K Sell
12,400
-8,900
-42% -$460K ﹤0.01% 1772
2023
Q2 		$1.2M Sell
21,300
-26,000
-55% -$1.48M ﹤0.01% 1352
2023
Q1 		$2.14M Buy
47,300
+6,600
+16% +$321K 0.01% 1037
2022
Q4 		$1.65M Sell
40,700
-2,100
-5% -$111K 0.01% 1002
2022
Q3 		$2.8M Buy
+42,800
New +$3.1M 0.02% 752
2022
Q2 		– Sell
-65,000
Closed -$4.08M – 1462
2022
Q1 		$4.08M Buy
+65,000
New +$4.08M 0.03% 660
2021
Q4 		– Sell
-13,400
Closed -$1.5M – 1628
2021
Q3 		$1.5M Sell
13,400
-9,500
-41% -$1.19M 0.01% 1040
2021
Q2 		$3.71M Sell
22,900
-1,100
-5% -$134K 0.03% 691
2021
Q1 		$2.92M Buy
+24,000
New +$3.62M 0.03% 607
2018
Q4 		– Sell
-10,400
Closed -$461K – 1907
2018
Q3 		$461K Buy
+10,400
New +$545K ﹤0.01% 1628

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Fund Management (CFM)'s CRSP Position: Q1 2026 in Review

Capital Fund Management (CFM) opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 95,770 shares worth $4.56M. The stake represents 0.02% of the portfolio and ranks #936 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in CRSP as recently as Q4 2024.

Capital Fund Management (CFM) first reported a position in CRSP in Q3 2018 and has held it in 18 quarters since. The position peaked at $14.1M in Q3 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Capital Fund Management (CFM) held 95,770 shares of CRISPR Therapeutics worth $4.56M as of Q1 2026.
  • CRISPR Therapeutics was a new Capital Fund Management (CFM) position in Q1 2026.
  • CRISPR Therapeutics made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #936 holding.
  • Capital Fund Management (CFM) first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 18 quarters since.
  • Capital Fund Management (CFM)'s CRISPR Therapeutics position peaked at $14.1M in Q3 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.